Cyclic AMP, calcium and control of cell growth  by Ralph, R.K.
Volume 161, number 1 FEBS 0770 
Cyclic AMP, calcium and control of cell growth 
R.K. Ralph 
Department of Cell Biology, University of Auckland, Auckland, New Zealand 
September 1983 
Review Letter 
Received 1 July 1983 
The role of cyclic AMP and calcium in the control of normal and tumour cell growth is considered in 
relation to the question whether cyclic AMP is a true mitogen or cc-mitogen. It is proposed that cyclic 
AMP normally controls the cell cycle at a point in Gl phase only by virtue of its ability to exclude calcium 
required by cells to progress past this point into S phase. Therefore increased influx of calcium by other 
routes induced by various factors can bypass the inhibitory effect of cyclic AMP and stimulate growth. 
In these circumstances cyclic AMP or calcium may or may not facilitate further progress into S phase 
according to the metabolic requirements of individual cells. The relevance to cancer cells is considered. 
Cyclic AMP Calcium 
1. INTRODUCTION 
The following short review and critique con- 
siders the role of cyclic AMP and Ca’+ in the con- 
trol of normal and tumour cell growth and par- 
ticularly the question whether cyclic AMP is a 
mitogen or co-mitogen. It is proposed that cyclic 
AMP is the normal inhibitor of the cell cycle only 
by virtue of its ability to exclude Ca2+ from cells 
in Gl phase and that increasing Ca” influx suffi- 
ciently in Gl can override the effect of cyclic AMP 
and stimulate growth. No attempt has been made 
to present all of the references relevant to the topic 
since most have been summarized in past and re- 
cent reviews referred to in the text. 
2. GROWTH INHIBITION BY CYCLIC AMP 
Numerous reviews and articles have summarized 
a multitude of facts suggesting that 
adenosine-3 ’ ,5 ’ -cyclic monophosphate (cyclic 
AMP) controls mammalian cell growth [l-12]. 
Some of the more pertinent observations are that 
growth-inducing agents such as serum usually 
decrease cyclic AMP in cells, that cyclic AMP will 
reverse the action of serum on growth, that agents 
Mitogen Growth control 
that increase cyclic AMP in cells often reduce 
growth, that there is an inverse relationship bet- 
ween intracellular cyclic AMP concentration and 
growth rate, that cyclic AMP or its analogues can 
inhibit growth and cause regression of some 
tumours, and that several tumour cell lines that do 
not respond to cyclic AMP contain mutant cyclic 
AMP-dependent protein kinases, illustrating the 
need for cyclic AMP-dependent protein 
phosphorylation to control their growth. Addi- 
tional support for possible control of the cell cycle 
by cyclic AMP comes from observations that cyclic 
AMP is a normal cellular metabolite and that high 
intracellular concentrations usually stop growth in 
Gl phase of the cell cycle, often restoring a mor- 
phology more like that attained during normal dif- 
ferentiation. Furthermore, it has been de- 
monstrated [13] that cyclic AMP is involved in 
growth arrest rather than progress through the cell 
cycle, supporting a negative or inhibitory role for 
cyclic AMP in growth control (for discussion see 
[12]). Also, the action of cyclic AMP requires 
transmission of the cyclic AMP signal via protein 
phosphorylation [14] and failure of cyclic AMP to 
inhibit growth has often been traced to alterations 
or defects in the transmission pathway [ 10,15-181. 
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Thus in toto there is considerable support for 
cyclic AMP as a pleiotypic mediator [19] control- 
ling the normal mammalian cell cycle. 
3. GROWTH STIMULATION BY 
CYCLIC AMP 
Recently the idea that cyclic AMP inhibits 
growth has been challenged, largely on the basis 
that cyclic AMP analogues or cyclic AMP- 
elevating agents such as cholera toxin or pros- 
taglandin El appear to act synergistically with 
various mitogens such as insulin or epidermal 
growth factor to stimulate DNA synthesis in some 
cells. These observations have led to proposals that 
cyclic AMP provides a mitogenic signal for 3T3 
cells [20,21] and that it stimulates DNA synthesis 
in other cells [22-251. Evidence for the positive 
control of proliferation of rat liver cells and thymic 
lymphocytes by Ca’+, cyclic AMP or the interplay 
of Ca’+ and cyclic nucleotides has also been 
presented [22-261 together with indications that 
calcium is necessary or possibly sufficient, for the 
initiation of cell growth in some systems [26-301. 
What then is the truth? Do different mechanisms 
control the growth of different cells, or is it 
possible to reconcile these apparently contradic- 
tory observations and provide a universal model 
for the control of mammalian cell growth? 
4. MITOGENS AND CALCIUM 
Current research has demonstrated that 
mitogens such as serum, insulin, epidermal growth 
factor, platelet-derived growth factor or lectins all 
affect Ca*+ availability or mobilize cations in cells 
[29-401. In particular it appears likely that an 
amiloride-sensitive Na+/H+ antiport is activated 
by many mitogens causing Na+ to enter cells in ex- 
change for H+ ions and provoking the subsequent 
exchange of intracellular Na+ for Ca*+ ions as oc- 
curs in other systems [33,36,41-461. As a conse- 
quence, numerous intracellular Ca*+-activated 
processes including carbohydrate metabolism 
phospholipid turnover, protein phosphorylation, 
microtubule depolymerisation, protease activa- 
tion, cyclic nucleotide phosphodiesterase activa- 
tion and altered mitochondrial metabolism could 
occur as part of a programme leading eventually to 
DNA synthesis as cells are propelled into cycle 
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[ 19,47-551. Depending upon its concentration 
and/or the availability of calmodulin or other fac- 
tors, elevated intracellular Ca*+ could also 
decrease cyclic AMP availability by inhibiting 
adenylate cyclase or stimulating cyclic nucleotide 
phosphodiesterase which would further reduce the 
restraints exerted by cyclic AMP on growth 
[56,57]. These and other observations uggest hat 
the intracellular (cytoplasmic?) Ca*+ concentration 
is critical for the initiation of cell growth and DNA 
synthesis, a conclusion supported by evidence that 
Ca*+ induces some cells to cycle [9,11,12], that 
removal of Ca*+ with EGTA usually negates the 
growth response [58-611 and that cyclic AMP 
levels rise in some cells when growth is inhibited by 
EGTA (J. Smart, unpublished). 
5. CYCLIC AMP AND Ca*+ AVAILABILITY 
The cyclic AMP analogue N6,02’-dibutyryl- 
adenosine 3 ’ ,5 ‘-cyclic monophosphate (DB cyclic 
AMP) blocks growth initiation by serum and other 
mitogens and Ca*+ influx into cells [8,29,30,61,62]. 
This raises the question whether the inhibition of 
growth by cyclic AMP is due solely to its ability to 
prevent excess calcium from entering cells at a 
critical growth restriction point [12] in Gl phase of 
the cell cycle. Some evidence that this could be true 
exists. Thus concanavalin A activation of small 
lymphocytes requires Ca*+ and the influx of Ca*+ 
into concanavalin A-treated cells is inhibited by 
DB cyclic AMP, as is DNA synthesis [29]. Further- 
more either DB cyclic AMP or EGTA prevents 
PY815 mouse mastocytoma cells from receiving a 
flux of Ca*+ required for growth [59] and either 
reagent inhibits the influx of Ca*+ and subsequent 
DNA synthesis upon restoration of serum to 
serum-deprived 3T3 cells [30]. Cyclic AMP also 
reduces Ca*+ availability in rat thymocytes and 
PC12 cells by stimulating Ca *+ extrusion and the 
Ca*+ ionophore A23187 can bypass the effect of 
cyclic AMP and stimulate thymocyte growth and 
PC12 cell adhesion [28,63,64]. In addition, A23 187 
short-circuits cyclic AMP-dependent mechanisms 
that decrease Ca2+ concentrations in platelets [6]. 
These and other observations uggest hat normal- 
ly cyclic AMP acts to decrease intracellular Ca*+ 
and that swamping the capacity of cyclic AMP to 
limit intracellular Ca*+ concentrations by opening 
new Ca*+ channels with mitogens, hormones or 
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ionophores permits intracellular Ca2’ concentra- 
tions to rise sufficiently to initiate those Ca2+- 
dependent processes required to activate cells (cf. 
[61,62]) allowing them to proceed into cycle while 
possibly, although not necessarily, simultaneously 
lowering cyclic AMP levels 1561. Having progress- 
ed beyond the critical Ca*+-dependent restriction 
point in Cl phase cells could then respond to in- 
creased cyclic AMP production induced by agents 
such as choleragen by activating various metabolic 
processes [48], and thereby enhancing cell cyclic 
progression. 
It is also possible that after Gl phase growth has 
initiated, later cyclic AMP-dependent events may 
be essential in some cells before DNA synthesis can 
eventually occur, explaining the apparent require- 
ment for cyclic AMP-dependent protein phosphor- 
ylation for initiation of DNA synthesis in Ca’+-de- 
prived rat liver or other cells blocked late in Gl 
phase or at the Gl/S phase boundary [I 1,22,25,27]. 
However, there appears to be no necessity for 
cyclic AMP-dependent events for S49 lymphoma 
mutants to progress through the cell cycle [12, 
13,66] so that either protein phosphorylation is not 
universally needed or the requirement for such 
cyclic AMP-dependent events is overcome in S49 
lymphoma and possibly other transformed or 
tumour sells [27]. 
After an initial Ca2’ influx initiates growth, fur- 
ther Ca’+-dependent events could also be necessary 
for some cells to progress into S phase since subse- 
quent removal of Ca2+ can prevent the onset of 
DNA synthesis [ll]. However, addition of DB 
cyclic AMP to cells that have progressed into S 
phase does not always prevent cell division, 
although it may delay or inhibit cells in G2 phase 
[5,8,59,67], suggesting either that the need for 
Ca2+ is past once cells enter S phase, or that the 
Ca2+ taken up during the initial influx is available 
or sufficient to sustain at least one cell division. 
Again the requirements for Ca2’ appear to be dif- 
ferent for normal and tumour cells (see below). 
6. IS CYCLIC AMP A MITOGEN? 
Conjecture that cyclic AMP alone directly 
assists cells to enter cycle or that it is a mitogen or 
co-mitogen is based partly on studies of the 
stimulatory effects of cyclic AMP or cyclic AMP- 
elevating agents (e.g., glucagon, cholera toxin) 
together with other mitogens (e.g., insulin) on the 
entry of quiescent 3T3 cells into S phase 
[20,21,24]. Unfortunately these studies did not 
measure intracellular Ca2+ concentrations or 
follow Ca2’ fluxes during growth stimulation so 
that no conclusions about effects on intracellular 
Ca2+ movement are possible. In these cir- 
cumstances it is dangerous to ignore the possibility 
that the reagents used (e.g., insulin, glucagon, 
prostaglandins) could have affected Ca*+ availabi- 
lity in the cells and that the true mitogenic effects 
resulted from Ca2’ action. Insulin [9,36,68], 
glucagon [69], and prostaglandins [70] are all 
known to affect cell membranes, ion transport and 
Ca*” availability in cells [48]. Furthermore cyclic 
AMP-elevating agents other than cholera toxin are 
not always effective in assisting growth [71]. 
Therefore the results of such experiments may de- 
pend upon whether the action of cyclic AMP or 
cyclic AMP-elevating agents on Ca2+ availability is 
overcome by the true mitogens. 
Similar conclusions, about cyclic AMP normally 
stimulating growth drawn from experiments in 
which cyclic AMP, protein kinases or protein 
kinase inhibitors initiate DNA synthesis when add- 
ed to cells whose growth is inhibited close to the 
Gl/S phase boundary, should also be viewed with 
caution since these observations may not reflect 
events at the normal G1 phase growth restriction 
point [22,23,25,27]. Furthe~ore, cyclic AMP is 
rapidly degraded by serum and by cells and it is 
doubtful whether the protein kinases or protein 
kinase inhibitors could enter cells. Therefore, it 
seems possible that these reagents may alter cell 
surfaces affecting membrane permeability and ion 
transport. The fact that isoproterenol raised cyclic 
AMP levels but did not initiate DNA synthesis in 
parotid glands in hypocalcemic thyroparathyroid- 
ectomized rats illustrates the need for Ca2’ and not 
just cyclic AMP production for DNA synthesis 
[26) . Effects on Ca” availability in some of these 
systems could also depend upon the source of the 
cells studied, since male and female rat liver cells 
respond differently to hormones [72]. Consequent- 
ly information regarding Ca2+ movement and 
availability is essential before intracellular cyclic 
AMP can be seriously considered as a true 
mitogen. 
In view of the above considerations it appears to 
be too early to conclude that cyclic AMP is a true 
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mitogen or to reject the conclusion that mam- 
malian cell growth is normally inhibited by cyclic 
AMP at a point in Gl phase of the cell cycle by 
depriving cells of sufficient Ca2+ for an event or 
events necessary for further cell cycle progression 
and that this is the main effect of cyclic AMP on 
the cell cycle, other later stimulatory effects of 
cyclic AMP merely arising from the widespread ac- 
tion of cyclic AMP and protein phosphorylation 
on metabolism [9,48]. In these circumstances in- 
creasing Ca2+ influx into the cytoplasm to levels 
exceeding the capacity of cyclic AMP to negate the 
influx would inevitably bypass the action of cyclic 
AMP and allow growth to proceed. Progression 
through the cell cycle may or may not require fur- 
ther cyclic AMP or Ca2+ action in different cells 
according to the nature of the cells and their in- 
dividual requirements for further cyclic AMP- or 
Ca2+-dependent metabolic events, while the 
necessary Ca2+ could be derived from intracellular 
sources replenished during the initial influx. It is 
possible that the cyclic AMP controlled restriction 
point in the cell cycle could correspond to Gn, the 
differentiation point in Gl described in [73] since 
various aspects of differentiation frequently ac- 
company inhibition of growth by cyclic AMP or its 
analogues [2,10,12,74]. 
7. CANCER CELL GROWTH 
There is a general belief that cancer cells have an 
altered or aberrant Ca2+ metabolism [ 11,75-771. 
For example, unusual features of cancer cells are 
that they will continue to grow at Ca2+ concentra- 
tions well below those required for normal cell 
growth [78-831 and that they contain higher Ca2+ 
concentrations than their normal counterparts 
[84-861. These observations could be explained if 
cancer cells have low ‘effective’ levels of cyclic 
AMP which allow intracellular Ca2+ concentra- 
tions to rise sufficiently to overcome Gl phase 
growth restriction (cf. [10,15,16]). However, other 
reasons for the higher Cazf in cancer cells are 
possible. These include altered cell membranes 
with additional or activated Ca2+ channels 
[36,76,85], altered mitochondrial function and 
CaZf metabolism [85,87-891, altered Ca2+ influx 
or efflux capacity 190-941, altered Ca2+ transport 
by membranes of the endoplasmic reticulum [94] 
and even the possible inability of some cancer cells 
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to exclude Ca2+ [91]. Because cyclic AMP is 
known to affect several of these processes it is also 
possible that either the multiple effects of low ‘ef- 
fective’ cyclic AMP, or independent alterations in 
any one or more of these functions could cause 
elevated intracellular Ca2+ and provoke growth of 
different cancer cells. 
Changes in the ratios, expression or distribution 
of different cyclic AMP-dependent and indepen- 
dent protein kinases or kinase subunits have been 
detected in proliferatively activated cells and 
tumour cells [95-1031 which could alter protein 
phosphorylation and modify Ca2+ fluxes, possibly 
as an initial consequence of reduced cyclic AMP 
[104]. However, because of the interlocked nature 
of the various mechanisms that control in- 
tracellular Ca2+ it is extremely difficult to discern 
which is the most important process controlling 
Ca2+ availability or which processes are unusual in 
individual tumour cells. Cytoplasmic Ca2+ is nor- 
mally maintained at such low concentrations 
(g 10e6 M) that relatively small changes in Ca2+ 
transport could be sufficient to alter significantly 
intracellular Ca2+ concentrations and induce 
Ca2’-dependent growth processes. 
Studies with amiloride suggest that quiescent 
cells have a minimally active amiloride-sensitive 
Na+ channel whereas mitogen-stimulated cells and 
tumour cells appear to have an active Na+ channel 
[32,33,41-43,105-1081. Increased Na+ influx via 
such channels could explain the higher Ca2+ in 
tumour cells since intracellular Na+ is known to 
exchange for extracellular Ca2+ in cells 
[36,45,48,109]. Furthermore, exchange of in- 
tracellular Na+ for protons could increase in- 
tracellular pH, further assisting cells into cycle 
[38,43,110-l 131. High intracellular Na+ is another 
common feature of rapidly proliferating cells or 
transformed cells that correlate with cell proiifera- 
tion [105,114]. The rapid stimulation of the 
Na+/K+ ATPase of liver cells by agents such as 
glucagon or epinephrine may also reflect increased 
Na+ influx since Na+ ions are known to increase 
Na+/K+ ATPase activity in other cells [I 15-1181. 
Exchange of Na+ with Ca2+ might then explain the 
ability of these hormones to induce DNA synthesis 
in liver cells blocked at the Gl/S phase boundary 
by Ca2+ deprivation [27]. 
As well as understanding the mechanisms that 
control intracellular Ca2+ concentrations it is im- 
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portant to define the specific event(s) in cells which 
require Ca*+ in order to initiate growth. Ca*+, like 
cyclic AMP, is a pleiotypic mediator that affects a 
wide variety of cellular processes [48,119]. 
Therefore co-ordinate control of growth by Ca2+ 
rather than control of one or two specific events or 
processes must be considered. Many effects of 
Ca*+ on cellular metabolism involve the 
Ca*+-binding protein calmodulin [86,119]. 
However, the recent discovery that protein kinase 
C, a Ca*+ and phospholipid-dependent, diacylgly- 
cerol-activated tyrosine-specific protein kinase is 
activated in cells by phorbol esters and that other 
mitogens such as insulin, epidermal growth factor 
and platelet-derived growth factor all activate 
similar tyrosine-specific protein kinases in cells 
raises the possibility that C type protein kinases 
could respond to Ca*+ influx by phosphorylating 
many proteins in cells to coordinately induce cell 
growth [120-1241. Therefore, just as Ca*+ and 
cyclic AMP act as synarchic messengers to control 
cellular metabolism [48] it is also likely that they 
are complementary pleiotypic mediators co- 
ordinating growth or quiescence. How better to 
achieve this than through protein phosphorylation 
controlled by different protein kinases uniquely 
switched on by Ca*+ or cyclic AMP? How better 
to subvert such a system than as the oncogenic 
viruses have done by increasing the production in 
cells of protein kinases not subservient o cyclic 
AMP [125-127]? Perhaps these viruses also alter 
Ca*+ transport mechanisms to ensure that the 
kinases are fully activated? 
In view of the above considerations it is now im- 
portant to identify precisely those actions of cyclic 
AMP and Ca*+ that control cell growth and to 
determine their metabolic consequences. It may 
then be possible to correct, or bypass these effects 
and eventually control or eliminate cancer cells in 
a logical manner. 
ACKNOWLEDGEMENTS 
This research was supported by grants from the 
Auckland Division, New Zealand Cancer Society 
and the New Zealand Medical Research Council. 
REFERENCES 
111 
PI 
[31 
[41 
PI 
WI 
[71 
181 
191 
WI 
Ull 
WI 
1131 
[I41 
WI 
1161 
[I71 
1181 
1191 
PO1 
WI 
WI 
Abell, C.W. and Monohan, T.M. (1973) J. Cell 
Biol. 59, 549-558. 
Pastan, I., Johnson, G.S. and Anderson, W.B. 
(1975) Annu. Rev. Biochem. 44, 491-522. 
Berridge, M.J. (1975) Adv. Cyclic Nucl. Res. 6, 
l-98. 
Friedman, D.L., Johnson, R.A. and Zeilig, C.E. 
(1976) Adv. Cyclic Nucl. Res. 7, 69-114. 
Friedman, D.L. (1976) Physiol. Rev. 56,652-708. 
Willingham, M.C. (1976) Int. Rev. Cytol. 44, 
319-363. 
Whitfield, J.F., MacManus, J.P., Rixon, R.H., 
Boynton, A.L., Youdale, T. and Swierenga, S. 
(1976) In Vitro 12, 1-18. 
Rebhun, L.I. (1977) Int. Rev. Cytol. 49, l-54. 
Rasmussen, H. and Goodman, D.B.P. (1977) 
Physiol. Rev. 57, 422-509. 
Schiinhofer, P.S. and Peters, H.D. (1977) in: 
Cyclic 3 ’ ,5 ’ -Nucleotides Mechanisms of Action 
(Cramer, H. and Schultz, J. eds) pp.107-131, 
Academic Press, New York. 
Whitfield, J.F., Boynton, A.L., MacManus, J.P., 
Sikorska, M. and Tsang, B.K. (1979) Mol. Cell. 
Biochem. 27, 155-179. 
Pardee, A.B., Dubrow, R., Hamlin, J.L. and 
Kletzien, R.F. (1978) Annu. Rev. Biochem. 47, 
715-750. 
Coffino, P., Gray, J.W. and Tomkins, G.M. 
(1975) Proc. Natl. Acad. Sci. USA 72, 878-882. 
Kuo, J.F. and Greengard, P. (1969) Proc. Natl. 
Acad. Sci. USA 64, 1349-1355. 
Goldberg, M.L., Burke, G.C. and Morris, H.P. 
(1975) Biochem. Biophys. Res. Commun. 62, 
320-327. 
Cho-Chung, Y.S. and Clair, T.S. (1976) Nature 
265, 452-454. 
Simantov, R. and Sachs, L. (1975) J. Biol. Chem. 
250, 3236-3242. 
Evian, D., Gottesman, M., Pastan, I. and 
Anderson, W.B. (1979) J. Biol. Chem. 254, 
6931-6937. 
Kram, R., Mamont, P. and Tomkins, G.M. 
(1973) Proc. Natl. Acad. Sci. USA 70,1432-1436. 
Rozengurt, E., Legg, A., Strang, G. and 
Courtenay-Luck, N. (1981) Proc. Natl. Acad. Sci. 
USA 78, 4392-4396. 
Rozengurt, E. (1981) Adv. Cyclic Nucl. Res. 14, 
429-442. 
Whitfield, J.F., Boynton, A.L., MacManus, J.P., 
Rixon, R.H., Sikorska, M., Tsang, B. and 
Walker, P.R. (1980) Ann. NY Acad. Sci. 339, 
216-240. 
5 
Volume 161, number 1 FEBS LETTERS September 1983 
[23] Boynton, A.L., Whitfield, J.F., MacManus, J.P., 
Armato, U., Tsang, B.K. and Jones, A. (1981) 
Exp. Cell. Res. 135, 199-221. 
[24] Friedman, D.L., Clams, T.H., Pilkes, S.J. and 
Pire, G.E. (1981) Exp. Cell. Res. 135, 283-290. 
[25] Gillies, R.J. (1982) Trends Biochem. Sci. 7, 
233-235. 
[26] Tsang, B.K., Whitfield, J.F. and Rixon, R.H. 
(1981) J. Cell. Physiol. 107, 41-46. 
[27] Boynton, A.L. and Whitfield, J. (1981) Adv. 
Cyclic Nucleotide Res. 14, 411-419. 
[28] Luckasen, J.R., White, J.G. and Kersey, J.H. 
(1974) Proc. Natl. Acad. Sci. USA 71, 5088-5090. 
[29] Tsien, R.Y., Pozzan, T. and Rink, T.J. (1982) 
Nature 295, 68-71. 
[30] Tupper, J.T., Del Rosso, M., Hazelton, B. and 
Zarquiotti, F. (1978) J. Cell. Physiol. 95, 71-84. 
[31] Rozengurt, E. and Mendoza, S. (1980) Ann. NY 
Acad. Sci. 339, 175-190. 
[32] Koch, K.S. and Leffert, H.L. (1979) Cell 18, 
153-163. 
[33] Villereal, M. (1981) J. Cell Physiol. 107, 359-369. 
[34] Moolenar, W.H., Yarden, Y., de Laat, S.W. and 
Schlessinger, J. (1982) J. Biol. Chem. 257, 
8502-8506. 
[35] Pershadsingh, H.A. and McDonald, J.M. (1979) 
Nature 28 1, 495-497. 
[36] Barritt, G.J. (1982) Trends Biochem. Sci. 6, 
322-325. 
[37] Resh, M.D., Nemenoff, R.A. and Guidotti, G. 
(1980) J. Biol. Chem. 255, 10938-10945. 
[38] Deutsch, C., Price, M.A. and Johansson, C. 
(1981) Exp. Cell. Res. 135, 359-369. 
[39] Wolff, H.J. and Akerman, K.E.O. (1982) Bio- 
chim. Biophys. Acta 693, 315-319. 
1401 Billah, M.M. and Lapetina, E.G. (1983) Proc. 
Natl. Acad. Sci. USA 80, 965-968. 
[41] Moolenar, W.H., Mummery, C.L., Van der Saag, 
P.T. and de Laat, S.W. (1981) Cell 23, 789-798. 
[42] Mummery, C.L., Boonstra, J., Van der Saag, 
P.T. and de Laat, S.W. (1982) Cell. Biol. Int. 
Reports 6, 654. 
[43] Pouyssegur, J., Chambard, J.C., Franchi, A., 
Paris, S. and Van Obberghen-Schilling, E. (1982) 
Proc. Natl. Acad. Sci. USA 79, 3935-3938. 
[44] Mastro, A.M. and Smith, M.C. (1982) J. Cell 
Biol. (Abstr.) 95, 21a. 
[45] Smith, R.L., Macara, I.G., Levenson, R., 
Housman, D. and Cantley, L. (1982) J. Biol. 
Chem. 257, 773-780. 
[46] Cassel, D., Pike, L.J., Grant, G.A., Krebs, E.G. 
and Glaser, L. (1983) J. Biol. Chem. 258,- 
2945-2980. 
[47] Van der Werve, G. (1981) Biochem. Biophys. Res. 
Commun. 102, 1323-1329. 
6 
[481 Rasmussen, H. (1981) Calcium and CAMP as 
Synarchic Messengers, Wiley, New York. 
1491 Egawa, K., Sacktor, B. and Takenawa, T. (1981) 
Biochem. J. 194, 129-136. 
[50] Billah, M.M. and Lapetina, E.G. (1982) J. Biol. 
Chem. 257, 11856-l 1859. 
]511 Thomas, J.M.F., Chap, H. and Douste-Blazy, L. 
(1982) Biochem. Biophys. Res. Commun. 103, 
8 19-824. 
[52] Kuo, J.F. (1980) Proc. Natl. Acad. Sci. USA 77, 
7039-7043. 
[53] Weisenberg, R.C. and Deery, W.J. (1981) Bio- 
them. Biophys. Res. Commun. 102, 924-931. 
1541 DeMartino, G.N. and Blumenthal, D.K. (1982) 
Biochemistry 21, 4297-4303. 
[55] Wernette, M.E., Ochs, R.S. and Lardy, H.A. 
(1981) J. Biol. Chem. 256, 12767-12771. 
[56] Ross, E.M. and Gilman, A.G. (1980) Annu. Rev. 
Biochem. 49, 533-564. 
[57] Wolff, D.J. and Brostrom, C.O. (1979) Adv. 
Cyclic Nucl. Res. 11, 28-88. 
[58] Diamantstein, T. and Ulmer, A. (1975) 
Immunology 28, 121-125. 
[59] Knightbridge, A.K. and Ralph, R.K. (1981) 
Molec. Cell. Biochem. 34, 153-164. 
1601 Boynton, A.L., Whitfield, J.F., Isaacs, R.J. and 
Morton, H.J. (1974) In Vitro 10, 12-17. 
[61] Berridge, M.J. (1976) SEB Symp. 30, 219-231. 
[62] Berridge, M.J. and Rapp, P. (1977) in: Cyclic 
3 ’ ,5 ’ -Nucleotides: Mechanisms of Action (Cra- 
mer, G.H. and Schultz, J. eds) pp.65-76, Wiley, 
New York. 
[63] Dani, A.M., Cittadini, A., Calviello, G., 
Festuccia, G. and Terranova, T. (1978) submitted. 
[64] Schubert, D., LaCorbiere, M., Whitlock, C. and 
Stallcup, W. (1978) Nature 273, 718-723. 
[65] Haslam, R.J., Lynham, J.A. and Fox, J.E.B. 
(1979) Biochem. J. 178, 397-406. 
[66] Darfler, F.J., Murakami, H. and Insel, P.A. 
(1980) Proc. Natl. Acad. Sci. USA 77,5993-5997. 
[67] Nomura, K., Hoshino, T., Knebel, K. and 
Barker, M. (1978) In Vitro 14, 174-179. 
[68] Czech, M.P. (1977) Annu. Rev. Biochem. 46, 
359-384. 
[69] Chen, J.-L.J., Babcock, D.F. and Lardy, H.A. 
(1978) Proc. Natl. Acad. Sci. USA75,2234-2238. 
[70] Carafoli, E. and Crompton, M. (1976) SEB 
Symp. 30, 89-115. 
[71] Pruss, R.M. and Herschman, H.R. (1979) J. Cell. 
Physiol. 98, 469-474. 
[72] Studer, R.K. and Borle, A.B. (1982) J. Biol. 
Chem. 257, 7987-7993. 
[73] Scott, R.E., Florine, D.L., Wille, J. J. and Yun, 
K. (1982) Proc. Natl. Acad. Sci. USA 79, 
845-849. 
Volume 161. number 1 FEBSLETTERS September 1983 
[74] Davis, J. and Ralph, R.K. (1975) Cancer Res. 35, 
1495-1501. 
[75] Wenner, C.E. (1975) in: Cancer, A 
Comprehensive Treatise (Becker, F.F. ed) ~01.3, 
pp.389-403, Plenum, New York. 
[76] Bygrave, F.L. (1976) in: Control Mechanisms and 
Cancer (Cris, W.E. et al. eds) pp.41 l-453, Raven, 
New York. 
[77] Cittadini, A., Bossi, D., Dani, A.M., Calviello, 
G., Wolf, F. and Terranova, T. (1981) Biochim. 
Biophys. Acta 645, 177-182. 
1781 Balk, S.D., Whitfield, J.F., Youdale, T. and 
Braun, A.C. (1973) Proc. Natl. Acad. Sci. USA 
70, 675-679. 
[79] Boynton, A.L. and Whitfield, J.F. (1976) Proc. 
Natl. Acad. Sci. USA 73, 1651-1654. 
[SO] Sweirengar, S.H., Whitfield, J.F. and Karasaki, 
S. (1978) Proc. Natl. Acad. Sci. USA 75, 
60696072. 
[Sl] Paul, D. and Ristow, H.J. (1979) J. Cell Physiol. 
98, 31-39. 
[82] Parsons, P.G. (1978) Austr. J. Exp. Biol. Med. 
56, 297-300. 
[83] Moore, L. and Pastan, I. (1978) Ann. NY Acad. 
Sci. 307, 177-193. 
1841 Lanone, K.F., Henington, J.G., Ohnishi, T., 
Morris, HP. and Williamson, J.R. (1974) in: 
Hormones and Cancer (McKerns, E. ed) 
pp.l31-167, Academic Press, New York. 
[85] Bygrave, F.L. (1982) in: The Role of Calcium in 
Biological Systems (Anghileri, L.J. and Tuffet- 
Anghileri, A.M. eds) ~01.1, CRC Press, Florida. 
[86] Criss, W.E. and Kakiuchi, S. (1982) Red. Proc. 
41, 2289-2291. 
[S?] Morton, R., Cunningham, C., Jester, R., Waite, 
M., Miller, N. and Morris, H.P. (1976) Cancer 
Res. 36, 3246-3284. 
1881 McCormack, J.G. and Denton, R.M. (1980) 
Biochem. J. 190, 95-105. 
[89] Denton, R.M., McCormack, J.G. and Edge& 
N.J. (1980) Biochem. J. 190, 107-117. 
[PO] Hazelton, B.J. and Tupper, J.T. (1981) Biochem. 
J. 194, 707-711. 
[91] Cittadini, A., Dani, A.M., Wolf, F., Bossi, D. 
and Calviello, G. (1982) Biochim. Biophys. Acta 
684, U-35. 
f921 Kawasaki, S., Suh, M.&I., Salas, M. and 
Raymond, J. (1980) Cancer Res. 40, 1318-1328. 
[93] Karasaki, S. and Okigaki, T. (1976) Cancer Res. 
36, 4491-4499. 
[94] Bygrave, F.L. (1978) Trends Biochem. Sci. 3, 
175-178. 
[95] Mednieks, M.I., Jungmann, R. and De Wys, 
W.D. (1982) Cancer Res. 42, 2742-2747. 
[96] Liversey, S.A., Kemp, B.E., Re Nicola, CA., 
Partridge, C. and Martin, J.J. (1982) J. Biol. 
Chem. 257, 14983-14987. 
[97] Mednieks, M-1. and Jungmann, R.J. (1982)Arch. 
Biochem. Biophys. 213, 127-138. 
1981 Ortez, R.A., Hersch, E.M. and Robinson, G.A. 
(1979) J. Cyclic Nucl. Res. 4, 87-96. 
[99] Kapoor, CL. and Cho Chung, Y.S. (1982) J. Ceil 
Biol. 95, 206a. 
[lo01 Handschin, J.C. and Eppenberger, U. (1979) 
FEBS Lett. 106, 301-304. 
I1011 Langan, T. (1980) Nature 286, 329-330. 
11021 Pena, J.M., Itarte, E., Domingo, A. and Cusso, 
R. (1983) Cancer Res. 43, 1172-1175. 
[103] Wittmaack, F.M., Weber, W. and Hilz, H. (1983) 
Eur. J. Biochem. 129, 669-674. 
[104] Vetter, R., Haase, H. and Will, II. (1982) FEBS 
Lett. 148, 326-330. 
11051 Sparks, R.L., POOL T.B., Smith, N.K. and 
Cameron, I.L. (1983) Crincer Res. 43, 73-77. 
DO61 O’Donnell, M.E. and Viilereal, L. (1982) J. Cell. 
Physiol. 113, 405-412. 
[107] Rozengurt, E. (1979) Cold Spring Harbor Conf. 
Cell Proliferation 6, 773-788. 
11081 Rozengurt, E. (1980) Ann. NY Acad. Sci. 339, 
175-190. 
[log] Sulakhe, P.S. and St Louis, P.J. (1980) Prog. 
Biophys. MoI. Biol. 35, 135-195. 
[l lo] Aronson, P.S., Nee, J. and Suhm, M.A. (1982) 
Nature 299, 161-163. 
[ 1111 Vigne, P., Frelin, C. and Lazolunski, M. (1982) J. 
Biol. Chem. 257, 9394-9400. 
[112] Zetterberg, A. and Engstrom, W. (1981) Proc. 
Natl. Acad. Sci. USA 78, 4334-4338. 
[I131 Schuldner, S. and Rozengurt, E. (1982) Proc. 
Natl. Acad. Sci. USA 79, 7778-7782. 
11141 Cameron, I.L. and Hunter, K.E. (1982) J. Cell. 
Biol. 95, 22a. 
11151 Kraus-Fredm~n, N., Hummel, L., Radominska- 
Pyrek, A., Little, J.M. and Lester, R. (1982) Mol. 
Cell. Biochem. 44, 173-180. 
[ 1161 Radoninska-Pyrek, S., Kraus-Friedmann, N., 
Lester, R., Little, J. and Denkins, Y. (1982) FEBS 
Lett. 141, 56-58. 
11171 Garay, R.P. and Garrahan, P.J. (1973) J. 
Physiol. 23 1, 297-325. 
[118] Smith, J.B. and Rozengurt, E. (1978) Proc. Natl. 
Acad. Sci. USA 75, 5560-5564. 
[119] Cheung, W.Y. (1980) Science 207, 19-27. 
[120] Kraft, A.S. and Anderson, W.B. (1983) Nature 
301, 621-623. 
11211 Weinstein, LB. (1983) Nature 302, 750. 
11221 Nishimura, J., Huang, J.S. and Deuel, T.F. 
(1982) Proc. Natl. Acad. Sci. USA 79,4303-4307. 
7 
Volume 161, number 1 FEBS LETTERS September 1983 
[123] Sahai, A., Smith, K.B., Panneerseluan, M. and 
Salomon, D.S. (1982) Biochem. Biophys. Res. 
Commun. 109, 1206-1214. 
[124] Roth, R.A. and Cassell, D.J. (1983) Science 219, 
299-301. 
[125] Kolata, G. (1983) Science 219, 377-378. 
11261 Wyke, J. (1981) Nature 290, 629-630. 
[127] Marx, J.L. (1982) Science 218, 983-985. 
8 
